secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001645113-25-000001
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NovoCure reports preliminary FY2024 net revenues $605M (+19% YoY); Q4 $161M (+21%)
--------------------------------------------------------------------------------

- Preliminary FY2024 net revenues $605.2M (+19% YoY); Q4 $161.3M (+21% YoY).
- Active patients globally: 4,126 total on TTFields; 4,077 Optune Gio; 52 Optune Lua prescriptions for NSCLC.
- Cash, cash equivalents and short-term investments $959.9M as of Dec 31, 2024.
- FDA approved Optune Lua for metastatic NSCLC in Oct 2024; Phase 3 PANOVA-3 trial met primary endpoint in pancreatic cancer.
- FY2025 revenue growth expected to align with Optune Gio active patient growth; US prior-period claims added $8.3M in Q4.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511325000001/0001645113-25-000001-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511325000001/nvcr-20250113.htm
  HTML page:      https://secwatch.observer/filing/0001645113-25-000001

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer